
What You Should Know:
– Zest Health, a leading innovator in virtual dermatology care, today announced a $13 million seed funding round led by Roivant Health.
– The company’s AI-powered platform provides personalized care for patients with inflammatory skin diseases like eczema and psoriasis, reducing unnecessary medication use and improving clinical outcomes. The investment will support Zest Health’s expansion and enable the company to scale its partnerships with health plans and employers.
Impact of Inflammatory Skin Disease
Millions of Americans struggle with inflammatory skin conditions, facing long wait times for appointments and often receiving rushed care from dermatologists. This has led to an overreliance on expensive systemic medications, particularly biologics, driving a significant increase in healthcare costs.
Zest Health is addressing this challenge with a virtual-first, value-based approach that prioritizes personalized care and cost-effectiveness. Zest Health partners with health plans and employers in value-based arrangements to improve the lives of their members and reduce healthcare costs.
The company’s focus on delivering value and achieving positive outcomes has earned it a Net Promoter Score (NPS) of 83. The company’s platform leverages patient data and AI to identify optimal treatment plans, including prescription medications, over-the-counter options, lifestyle changes, and preventative interventions.
Key benefits of the platform include:
Personalized Care: AI-powered platform analyzes patient data to identify the most effective treatment plan for each individual.
Reduced Medication Use: Minimizes unnecessary reliance on expensive systemic medications, particularly biologics.
Improved Outcomes: Over 80% of patients see disease improvement as measured by Body Surface Area (BSA) and the Dermatology Life Quality Index (DLQI).
High Patient Satisfaction: Over 90% of patients prefer Zest to their prior dermatology experiences.
Cost Savings: Reduces pharmacy spend by thousands of dollars per enrollee annually.
“As a psoriasis patient myself, I know that the status quo fails to deliver ongoing support and lasting relief,” said Zest Health CEO Olivia Deitcher. “At Zest, we have flipped traditional dermatology care on its head by providing radical access and personalized care so flaring patients get expert help during and in between flares, without overreliance on biologics.”